Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Additional myeloablation with 52Fe before bone marrow transplantation

C Jacquy1, A Ferrant, N Leners

  • 1Department of Hematology, Catholic University of Louvain, Belgium.

Bone Marrow Transplantation
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis.

European journal of nuclear medicine and molecular imaging·2021
Same author

Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis.

European journal of nuclear medicine and molecular imaging·2020
Same author

<sup>90</sup>Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours.

Physics in medicine and biology·2018
Same author

Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline.

European journal of nuclear medicine and molecular imaging·2018
Same author

Translocation (14;19)(q32;q13.1) in a Young Patient who Developed a Large Cell Lymphoma after an Initial Diagnosis of CLL.

Leukemia & lymphoma·2016
Same author

Practical Epidemiology.

Acta clinica Belgica·2016

Iron-52 (52Fe) therapy before bone marrow transplantation (BMT) may improve outcomes for hematological malignancies. This approach boosted radiation to the bone marrow without excessive toxicity, showing potential for better disease-free survival.

Area of Science:

  • Hematology
  • Oncology
  • Nuclear Medicine

Background:

  • High-dose chemoradiotherapy followed by bone marrow transplantation (BMT) is a primary curative treatment for hematological malignancies.
  • Relapse and toxicity are significant challenges limiting the success of BMT.
  • Selective dose escalation to bone marrow (BM) while sparing normal organs is crucial for improving BMT efficacy.

Purpose of the Study:

  • To evaluate the safety and efficacy of iron-52 (52Fe) therapy administered before conventional BMT conditioning.
  • To determine if 52Fe can selectively increase radiation dose to the bone marrow.
  • To assess the impact of 52Fe therapy on disease-free survival (DFS) and toxicity in high-risk BMT patients.

Main Methods:

  • A phase II clinical study involving 24 high-risk BMT patients.

Related Experiment Videos

  • Administration of 52Fe prior to standard BMT conditioning regimens.
  • Measurement of radiation-absorbed dose (RAD) to bone marrow and liver.
  • Monitoring of patient outcomes, including relapse rates and toxicity.

    • Main Results:

    • The median 52Fe dose was 59 mCi, delivering a median RAD of 626 rad to the BM and 338 rad to the liver.
    • No significant adverse effects were observed following 52Fe administration.
    • Hematopoietic recovery occurred without toxicity exceeding that of conventional conditioning alone.
    • The 3-year DFS probability was 49%, with 8 relapses observed.

    Conclusions:

    • 52Fe therapy is a potentially safe method to augment radiation dose to the bone marrow before BMT.
    • This approach may offer a way to improve outcomes for patients with marrow-based diseases undergoing BMT.
    • Further investigation is warranted to confirm the benefits of 52Fe in enhancing disease control and survival.